Clinical trial
Safety Study of Parathyroid Hormone in Patients Needing Additional Stem Cell…
NCT00299780 · Massachusetts General Hospital, Other · Completed
Key facts
| NCT number | NCT00299780 |
|---|---|
| Title | Safety Study of Parathyroid Hormone in Patients Needing Additional Stem Cell Mobilization. |
| Official title | Phase I Study of Parathyroid Hormone in Combination With G-CSF in Patients Requiring Additional Stem Cell Mobilization |
| Lead sponsor | Massachusetts General Hospital, Other |
| Collaborators | Dana-Farber Cancer Institute Beth Israel Deaconess Medical Center |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Lymphoma, Multiple Myeloma, Acute Myelogenous Leukemia |
| Intervention type | Drug |
| Interventions | Stem cell mobilization |
| Enrollment | 12 |
| Start date | Jul 1, 2004 |
| Completion | Apr 1, 2007 |
| First posted | Mar 7, 2006 |
| Last update posted | Apr 24, 2007 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: